One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Biomarkers Market

[ 英語タイトル ] Biomarkers Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0089083
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 114
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Abbott Laboratories, Inc.
- Aushon Biosystem
- Bio-Rad Laboratories
- Epigenomics AG
- Epistem Ltd
- Johnson & Johnson
- Qiagen N.V
- Roche Diagnostics
- Siemens Healthcare GmbH
- Thermo Fisher Scientific Inc.

[Report Description]

A biomarker refers to a biological molecule or gene that is used to effectively and accurately evaluate pharmacologic responses, pathogenic procedures, and biological procedures. Also known as a molecular marker or signature molecule, biomarkers are found in blood, other body fluids, and tissue.

The global market for biomarkers is gaining traction from a number of factors, including increasing prevalence and diagnosis of life-threatening diseases like cancer, cardiovascular diseases, neurological disorders, etc., which is, in turn, raising the awareness and increasing the demand for early diagnosis, reducing the cost of clinical trials in various emerging economies, increasing investment in research and development by biotechnology and pharmaceutical companies, and new initiatives regarding biomarker research. On the other hand, the biomarkers market is facing challenges from high capital investments, the low cost-benefit ratio with total investment, and poorly suited regulatory and reimbursement systems. Nevertheless, vastly populated emerging economies in the Asia Pacific such as India and China are expected to open new revenue avenues for the companies operating in the biomarkers market, provided they can prove the clinical validity of the tests.

Key Market Trends

Cancer Biomarkers dominate the market

Development of advanced genomic analysis technique, the introduction of effective guidelines for biomarkers manufacturing, huge amount of research by Cancer societies and proven effectiveness of transplants are some of the primary growth stimulants for the segment. Although manufacturing and pharmacological issues and regulatory hurdles are hindering the growth of the market, the development of products from research institutes has been propelling the growth of this market. For instance, in January 2018, Researchers from University of Luxembourg have discovered a new biomarker for colorectal cancer which classifies patients into “high” and “low” risk group which may help oncologists to choose the adequate treatment for a particular patient.

North America Dominates the Market in the Forecast Period

North America currently dominates the market for renal biomarkers and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. Over the past decade, there has been a significant increase in the number of USFDA-approved drug labels containing information on molecular biomarkers. Almost every pharmaceutical company has been developing molecular biomarker programs, either through partnerships or through other ventures. Molecular biomarkers are expected to be identified and validated in drug development and be used to support the approval of drug products. Such drug approvals are helping the renal biomarkers market grow in the United States.

Competitive Landscape

Majority of the biomarker assays and tests are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, due rise of awareness and hence increasing market, Asia-pacific is witnessing an emergence of some small players.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Life Threatening Diseases
4.2.2 Increasing Demand for Early Diagnosis of Diseases
4.2.3 Research Advancements in finding new Biomarkers
4.3 Market Restraints
4.3.1 Issues Related to Regulatory and Reimbursment Systems
4.3.2 High Cost of Biomarkers
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Disease
5.1.1 Cancer
5.1.2 Cardiovascular Disorders
5.1.3 Neurological Disorders
5.1.4 Immunological Disorders
5.1.5 Renal Disorders
5.1.6 Others
5.2 By Type
5.2.1 Prognostic Biomarkers
5.2.2 Prognostic Biomarkers
5.2.3 Pharmacodynamic Biomarkers
5.2.4 Surrogate End Point Markers
5.3 By Mechanism
5.3.1 Genetic biomarkers
5.3.2 Epigenetic biomarkers
5.3.3 Proteomic biomarkers
5.3.4 Lipidomic biomarkers
5.3.5 Others
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Abbott Laboratories, Inc.
6.1.2 Aushon Biosystem
6.1.3 Bio-Rad Laboratories
6.1.4 Epigenomics AG
6.1.5 Epistem Ltd
6.1.6 Johnson & Johnson
6.1.7 Qiagen N.V
6.1.8 Roche Diagnostics
6.1.9 Siemens Healthcare GmbH
6.1.10 Thermo Fisher Scientific Inc.




Recommended reports